Liquid buprenorphine formulations
US9918981B2 · kind B2 · utility
4Cited by
6References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 27, 2016 |
| Grant date | Mar 20, 2018 |
| Priority date | — |
| Expiry date | Oct 27, 2036 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K47/40
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides liquid formulations containing buprenorphine, a pharmaceutically acceptable salt thereof, or a derivative thereof. The invention further provides liquid formulations containing buprenorphine and naloxone, pharmaceutically acceptable salts thereof or derivatives thereof. The invention further provides a method of treating pain or opioid dependence by administering liquid formulations containing buprenorphine or a combination of buprenorphine and naloxone, a pharmaceutically acceptable salt thereof, or a derivative thereof to a patient in need thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.